Title of article :
Tumour Necrosis Factor-Alpha as a New Therapeutic Target for Rheumatoid Arthritis: An Update
Author/Authors :
Giasuddin, ASM Medical College for Women Hospital - Deptt of Biochemistry , Hoque, ME Medical College for Women Hospital - Deptt of Medicine , Ahmed, ZU Medical College for Women Hospital - Deptt of Medicine
From page :
88
To page :
94
Abstract :
In rheumatoid arthritis (RA), the conventional therapies (first-line, secondline, third-line drugs) provide more or less effective symptomatic relief for a decade or so from the onset ofthe disease. However, the chronic inflammatory destructive processes involving connective tissue, cartilage and bone with their attendant disability progress relentlessly in majority of patients. Secondly, use of second-line and third-line drugs in RA are limited due to their side effects. Studies in animals and RA patients have confirmed that tumour necrosis factor-alpha (TNF(Alpha)), an inflammatory cytokine, is of major importance in the rheumatoid disease process and thus, it might be an effective therapeutic target in RA. Animal model experiments and clinical trials were conducted with anti-TNF(Alpha) monoclonal antibody (anti-TNF(Alpha) MoAb) in RA recently. This anti-TNF(Alpha) MoAb therapy was found to be both effective and safe which documented the coming-of-age of cytokine-based immunointervention in RA. Researchers are optimistic that modern medicine would certainly witness the application ofthis noble immunotherapy enabling to selectively target cytokines, e.g. TNF(Alpha), in RA as well as in other inflammatory autoimmune diseases in the near future.
Journal title :
Bangladesh Medical Research Council Bulletin
Journal title :
Bangladesh Medical Research Council Bulletin
Record number :
2671743
Link To Document :
بازگشت